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Abstract
Background: Triple-negative breast cancers represent an important clinical challenge, as these cancers do not respond
to conventional endocrine therapies or other available targeted agents. Phycocyanin (PC), a natural, water soluble and
non-toxic molecule is shown to have potent anti-cancer property.
Methods: In this study, we determined the efficacy of PC as an anti-neoplastic agent in vitro on a series of breast cancer
cell lines. We studied effects of PC in inducing DNA damage and apoptosis through western blot and qPCR. Also, anti-
metastatic and anti-angiogenic properties were studied by classic wound healing and vasculogenic mimicry assays.
Results: We found that triple negative MDA-MB-231 cells were most sensitive to PC (IC50 : 5.98 ± 0.95 μM) as compared
to other cells. They also showed decreased cell proliferation and reduced colony formation ability upon treatment with
PC. Profile of Cell cycle analysis showed that PC caused G1 arrest which could be attributed to decreased mRNA levels of
Cyclin E and CDK-2 and increased p21 levels. Mechanistic studies revealed that PC induced apoptosis as evident by
increase in percentage of annexin positive cells, increase in γ-H2AX levels, and by changing the Bcl-2/Bax ratio followed
by release of cytochrome C and increased Caspase 9 levels. MDA MB 231 cells treated with PC resulted in decreased cell
migration and increased cell adhesive property and also showed anti-angiogenic effects. We also observed that PC
suppressed cyclooxygenase-2 (COX-2) expression and prostaglandin E(2) production. All these biological effects of
phycocyanin on MDA MB 231 cells could be attributed to decreased MAPK signaling pathway. We also observed
that PC is non-toxic to non-malignant cells, platelets and RBC’s.
Conclusion: Taken together, these findings demonstrate, for the first time, that PC may be a promising
anti-neoplastic agent for treatment of triple negative breast cancers.
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Background
Cancer of the mammary gland is a complex disease with
no known single cause that continues to be a worldwide
killer and is the most frequent among cancer related
mortality in women [1, 2]. Triple-negative breast cancer,
hallmarked by tumors that lack estrogen receptor (ER),
progesterone receptor (PR), and HER-2 genes, represent
significant clinical challenge as these cancers are highly
aggressive and are resistant to conventional endocrine
therapy and suffers lack of targeted therapies [3].
Current therapeutic strategies for triple-negative disease
include anthracycline/taxane combinations, platinum
agents, and other DNA damaging agents. Recently,
EGFR targeted therapy has been projected as a single
therapeutic mechanism in triple-negative breast cancer,
but results were varied [4]. Therefore, there is an in-
creasing need to explore for alternate therapeutic op-
tions for these patients.
Therapeutic alternatives originating from food or food
supplements appear to be growing in popularity as
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“nutritional therapy” and are well studied for their che-
mopreventive and chemotherapeutic effects [5]. Investi-
gations of several food derived bioactive compounds
revealed their ability to antagonize dysregulated targets
in cellular signaling pathways to exert their anti-
neoplastic activities [6]. Thus isolating these bioactive
molecules present in marine/land food products, deter-
mining their broad range pharmaceutical activity, dedu-
cing their specific molecular targets and establishing
their minimal toxicity to normal tissues could aid in
treatment of cancer [7]. Phycocyanin is an important
molecule extracted from the algae Arthrospira platensis.
It is a natural, water soluble and non-toxic molecule
with potent anti-cancer, anti- oxidant and anti-
inflammatory properties [8, 9]. Particularly, it is shown
to have anti-cancer activity against colon, [10] hepatocel-
lular, [11] cervical [12] and leukemic cell lines [13].
It is widely accepted that critical genes involved in
transforming mammary epithelial cells encode proteins
that function as dynamic regulators of signal–transduc-
tion pathways that regulate cell cycle, differentiation,
proliferation and survival [14]. In addition, several
groups have established that numerous signaling path-
ways important for normal breast development are also
dysregulated during the progression of breast cancer
[15]. Mitogen-activated protein kinase (MAPK) is one
such important signaling kinase involved in breast can-
cer progression [16, 17].
In our study, we studied the role of phycocyanin as an
anti-neoplastic agent in triple- negative breast cancer
cells for the first time and revealed the molecular mech-
anism behind its anti-cancer activity.
Methods
Materials
PC (Parry India Ltd, India) was dissolved in phenol red
free DMEM to prepare a stock solution (200 μM) and
stored at 4 °C. Dulbecco’s Modified Eagle Medium
(DMEM), fetal bovine serum (FBS) and 0.25 % Trypsin-
EDTA were procured from Invitrogen (Carlsbad, CA).
Supplements for cell culture were purchased from Sigma
Aldrich (St. Louis, MO) and Hi-media. (Mumbai, India)
Neutral red was purchased from Sigma Aldrich (St.
Louis, MO). Annexin V-FITC Apoptosis Detection Kit
was purchased from BD Biosciences (San Jose, CA). The
inhibitor cocktail was obtained from Pierce (Rockford,
IL) and antibodies against ERK1/2, γH2AX (Ser 139),
COX-2, cytochrome C, p-65, AKT and Vinculin were
from Cell Signaling Technology (Beverly, MA). Respect-
ive secondary mouse, rabbit and goat antibodies were
from Santa Cruz Biotechnology (Santa Cruz, CA). En-
hanced chemiluminescence solution was from GE health
care. Primers for Cyclin E, CDK-2, p-21, Bax, Bcl-2,
Caspase 9, Mcl-1,MMP-9,VEGFR-2 and GAPDH were
obtained from Eurofins (Luxembourg, Europe). C-DNA
reverse transcriptase kit was procured from ABI (Carlsbad,
CA) and SYBR green PCR master mix was from
Roche (BASEL, Switzerland). Alexa Flour was from
Life Technologies (Carlsbad, CA). PGE-2 kit was ob-
tained from Cayman chemicals (Ann Arbor, MI).
Matrigel was obtained from BD Biosciences (San
Jose, CA, USA).
Methods
Cell lines and cell culture
Human breast cancer cell lines MDA-MB-231 and
MCF-7 (procured from NCCS, Pune) SKBR-3, BT-474
and HBL-100 (kindly provided by Dr. Rayala Suresh
Kumar, IIT-M) were cultured in high glucose (4.5 g/l)
DMEM medium supplemented with 10 % fetal bovine
serum,100 units/ml Penicillin, 100 mg/ml Streptomycin,
pH 7.4 in 25 cm2, tissue culture flasks at 37 °C under
5 % CO2 and 95 % air. Human Breast Normal cell line
MCF 10A (a gift from Dr. Annapoorni Rangarajan, IISC,
Bangalore) were cultured in DMEM-F12 supplemented
with NaHCO3 (1.2 g/L), 10 % HS, antibiotic/antimycotic
mixture (1 %), EGF (20 ng/ml), HC (500 ng/ml), Cholera
Toxin (100 ng/ml) and were maintained at 37 °C in 5 %
CO2,95 % air and passaged thrice a week.
PC treatment
Initially a dose–response study was carried out to deter-
mine the suitable dose for inhibition of cell growth and
induction of apoptosis. Accordingly, the dosage and time
points varied between parameters studied and are de-
scribed in the respective methods.
Neutral red staining assay
Cells 2 x 104 were seeded in 96-well plates a day prior to
treatment. Cell viability for the treated cells (1-20 μM/
PC) was examined after 24 h by using neutral red assay
as outlined by Guillermo et al. [18]. Briefly, post drug
treatment neutral red (40 μg/ml) was added and after
2 h incubation at 37 °C the plate was washed and the
dye was extracted with acidified ethanol solution. Ab-
sorbance was read at 540 nm and cell viability was ascer-
tained by measuring the absorbance of the treated cell
and comparing it to untreated negative controls.
Clonogenic assay
500 viable cells were seeded in 60 mm plates and were
allowed to attach overnight. Cells were incubated with 1,
3 and 5 μM/PC for 24 h and then incubated for an add-
itional 10 days in complete medium to allow colonies to
form. The colonies obtained were washed with PBS,
fixed in methanol, followed by staining with crystal vio-
let. Experiments were done in triplicate. The colonies
were counted and compared to controls.
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Scratch assay /In vitro cell migration assay
5 x 105 cells/well were grown on 6 well plates to form
confluent monolayer. Gaps were created in confluent
cell layers using micropipette tips, followed by a rinse
with PBS. Cells were treated with 3 μM/PC and as con-
trol, cells growing in complete media were maintained.
The wound closure was monitored by phase-contrast
microscopy and photographed at the 0th and 24th hour.






Hanging drop aggregation assay
Cells grown to sub confluence in culture plates were ex-
posed to 3 μM/PC for 24 h and harvested. The cells
were re-suspended in complete media and 20 μL of the
cell suspension containing approximately 5000 cells was
placed onto the inner surface of the lid of the petri dish,
which was then placed on the petri dish containing
serum free media (such that the drops hang from the lid
with the cells suspended within them). After overnight
incubation at 37 °C the lid was inverted, cells were pipet-
ted 10 times and images were documented using 10X
objective of a phase contrast microscope.
Actin dynamics study using confocal microscopy
Cells were plated onto glass coverslips in culture dishes
and allowed to attach overnight. After a 24 h treatment
to 3 μM/PC cells were fixed for 20 min in 1 % parafor-
maldehyde (PFM) followed by incubation in 0.1 M gly-
cine solution for 5 min. Cells were permeabilized using
0.1 % Triton X 100 for 3–5 min. A series of PBS rinse
was given after which 5U of phalloidin was added and
incubated in dark for 45 min. Cells were counter stained
with propidium iodide (300 μg/mL) and mounted on
DPX and observed under the confocal microscope at
488 nm.
Cell cycle analysis by flow cytometry
Cells (2 x 105) were seeded in 60 mm plates and syn-
chronized by culturing them in serum free medium.
After 24 h treatment with 5 μM/PC both adherent and
floating cells were collected, washed twice with cold
PBS, and stained with hypotonic propidium iodide solu-
tion (50 μg/ml PI, 40 μg/ml RNAse A, 0.3 μl/ml Triton
X 100 in 0.1 % trisodium citrate) for 15 min. Stained
cells were analyzed by flow-cytometry using BD Accuri
C6 (Becton Dickinson, San Jose, CA) at 488 nm captur-
ing 20,000 events.
Annexin V PE and 7AAD staining
Cells (1 × 106) were seeded in 100 mm plates and
allowed to attach overnight. Next cells were treated with
1 μM (IC25) and 5 μM (IC50) PC for 6 h. Following
treatment cells were harvested and stained using
Annexin V-phycoerythrin (PE) apoptosis detection kit
(BD Pharmingen) according to the manufacturer’s rec-
ommendations. Briefly, the cells were trypsinized,
washed in PBS, and resuspended in binding buffer (1 ×
106/mL). Equal volumes of Annexin V-PE and 7-amino-
actinomycin D (7-AAD) were added and incubated for
15 min at room temperature in the dark and analyzed
by flow-cytometry.
RNA isolation and real-time reverse transcription-PCR
Cells (1 x 106) were seeded in 100 mm plates and
allowed to attach overnight. Next cells were treated with
5 μM/PC for cell cycle and apoptotic related gene ex-
pression studies and 3 μM/PC for migration and angio-
genesis related gene expression studies for 24 h. Total
RNA was isolated from untreated and drug-treated cells
using Trizol reagent. The yield and purity of isolated
RNA was checked by UV spectrophotometry. 2 μg of
total RNA were used in reverse transcription reactions
using the C-DNA reverse transcriptase kit according to
manufacturer’s protocol. Gene expression in untreated
and PC - treated cells were determined by real-time
PCR using the reverse transcription product, gene-
specific primers (5 pmol) and SYBR green in a 20 μL re-
action volume on the 7500 Fast RT PCR machine (ABI,
Carlsbad, CA). Relative changes in mRNA expression
levels were assessed by the 2-ΔΔCT method and changes
in mRNA expression of the target gene were normalized
to that of GAPDH gene. The primer pairs of the selected
genes are listed in Table 1.
Protein extraction, SDS-PAGE & Western blot analysis
Cells (1 × 106) were seeded in 100 mm plates and
allowed to attach overnight and treated with 3 μM/PC at
time points described in figures. For whole cell protein,
lysates were collected using RIPA buffer containing pro-
tease/phosphatase inhibitor cocktail. For nuclear protein,
first cytoplasmic extract was collected using buffer A
(1 M HEPES pH 7.9, 2 M KCL,o.5 M EDTA pH 8,
0.1 M EGTA pH 7, 0.1 M DTT, 10 % NP40, protease in-
hibitor) and later nuclear protein extract were collected
using buffer B(1 M HEPES pH 7.9, 5 M Nacl,o.5 M
EDTA pH 8, 0.1 M EGTA pH 7, 0.1 M DTT and protease
inhibitor). The protein concentrations were measured
using Bio-Rad protein estimation kit, spectrophotometric-
ally. Equivalent amounts of protein lysates were separated
by electrophoresis in 12 % SDS polyacrylamide gel and
blotted onto nitrocellulose membrane. The blotted mem-
branes were incubated with different primary antibodies,
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followed by incubations with secondary antibodies. The
proteins were visualized using an ECL kit.
PGE2 assay
Amounts of PGE2 in the conditioned media collected
from the arachidonic acid stimulated (10 μM) PC-
treated (5 μM/PC) cells were determined by an enzyme-
linked immunosorbent assay according to the instruc-
tions of the manufacturer (Cayman chemicals).
Assay for vasculogenic mimicry
A 96-well tissue culture plate was evenly coated with
50 μl/well growth factor-reduced matrigel, which was
allowed to solidify at 37 °C for 45 min. The cell suspen-
sion containing 3 μM/PC was added (200 μl /well) onto
the surface of the matrigel and incubated at 37 °C. Cells
were monitored through 2-10 h and photographed using
a phase contrast microscope.
Platelet aggregation assay
Briefly, 1 mL of whole blood was collected in a heparin
vaccutainer and spun. Platelets were concentrated in
1 mL of RPMI 1640 and treated to 20 μM/PC, the highest
dose used in initial testing. PBS and collagen were
maintained as negative and positive controls respectively.
Following 10 min incubation a drop of the cell suspension
was placed on glass slides and observed for any ag-
gregation under 10× magnification of a phase contrast
microscope.
Hemolytic assay
Briefly, 1 mL of whole blood was collected in a heparin
vaccutainer and spun. The RBC pellet was re-suspended
in 1 mL of RPMI 1640 to which 20 μM/PC was added.
RBC’s exposed to 0.1 % Triton X 100 were maintained
as a positive control. After 2 h incubation at 37 °C, cells
were spun and re-suspended in PBS. A drop of the cell
suspension was placed on glass slides and observed for
any morphological changes under 40× magnification of a
phase contrast microscope.
Statistical analysis
All the experiments were performed at least three times,
independently. The data obtained were expressed as
‘mean ± standard deviation’. Wherever appropriate, the
data were subjected to Student’s t-test using Graph Pad
Prism Version 5.0. A value of p < 0.05 was considered as
significant.
Table 1 List for primer pairs used in qPCR
Gene Orientation Primer sequence 5′ TO 3′ Accession number
CYCLIN E F TCAGGGTATCAGTGGTGCGA XM_005259370.2
R CAAATCCAAGCTGTCTCTGTG
CDK-2 F TTTGCTGAGATGGTGACTCG NM_001798.4
R CTTCATCCAGGGGAGGTACA
P21 F AAG ACC ATG TGG ACC TGT NM_001291549.1
R GGT AGA AAT CTG TCA TGC TG
BAX F TGCTTCAGGGTTTCATCCAG NM_001291428.1
R GGCGGCAATCATCCTCTG
Bcl-2 F AGGAAGTGAACATTTCGGTGAC NM_000633.2
R GCTCAGTTCCAGGACCAGGC
CASPASE 9 F CCAGAGATTCGCAAACCAGAGG XM_011542273.1
R GAGCACCGACATCACCAAATCC
MCL1 F GGGCAGGATTGTGACTCTCATT NM_001197320.1
R GATGCAGCTTTCTTGGTTTATGG
COX-2 F GATACTCAGGCAGAGATGATCTACCC NM_000963.3
R AGACCAGGCACCAGACCAAAGA
VEGFR2 F TGCCTACCTCACCTGTTTC NM_002253.2
R GGCTCTTTCGCTTACTGTTC
MMP-9 F ACCTCGAACTTTGACAGCGAC NM_004994.2
R GAGGAATGATCTAAGCCCAGC
GAPDH F ACCCAGAAGACTGTGGATGG NM_001289746.1
R CAGTGAGCTTCCCGTTCAG
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Results
PC inhibits proliferation and colony formation ability of
breast cancer cells
Screening for anti-cancer effects of PC by neutral red
uptake assay on breast cancer cells representing different
molecular subtypes and on Normal Human Breast cells
showed that PC inhibited proliferation of breast cancer
cells in a dose dependent manner. The IC50 values for
the tested panel of breast cancer cells ranged between 5
and 15 μM (Table 2). It was interesting to note that
triple negative MDA MB 231 cells were found to be
most sensitive to PC with an IC50 of 5.98 μM in as early
as 24 h and hence used as a representative cell line for
further experiments (Fig. 1a). There is no significant ef-
fect of PC on normal Human Breast MCF 10A cells in-
dicating its non-toxicity to normal cells. Upon treatment
with PC, we observed a change in cell morphology
-comparable to morphological changes associated with
apoptosis (Fig. 1b).
Further to establish the inhibitory role of PC on trans-
forming properties of cancer cells, we performed clono-
genic assay. Results showed that PC treated cells showed
significant reduction in colony formation when com-
pared to controls, indicative of potent inhibition of cell
growth and reproductive integrity (Fig. 1c).
PC inhibits wound healing and migration of MDA MB 231
breast cancer cells
Reduced clonogenecity is usually associated with loss of
invasion capabilities of tumor cells [19]. Since PC treated
cells showed a significant reduction in colony formation
ability, we next sought to determine the effects of PC on
the migration behavior of breast cancer cells. Classic
wound healing assay results showed that PC treated cells
showed decreased wound healing in comparison to con-
trol. The percentage of wound closure in PC treated
group decreased to 16.2 ± 3.06 % Vs 89.8 ± 2.34 % in the
control group (Fig. 2a). Further, we determined the effect
of PC on the phenotypic characteristics associated with
metastatic activity by hanging drop aggregation assay.
Results showed that there is an increased adhesiveness
with > 20 aggregates/field in PC treated group. The aver-
age aggregates per field with a 3 μM dose of PC were
23.3 ± 1.3 Vs 10.3 ± 2.15 in control (Fig. 2b). Addition-
ally, this disruption of cellular motility was microscopic-
ally analyzed by phalloidin stain to visualize actin
filaments. As indicated by arrow head, PC treated cells
showed collapsed actin cytoskeleton when compared to
the untreated control (Fig. 2c). Collectively these results
suggest that PC could inhibit cell migration via cytoskel-
eton disruption and also confer adhesiveness to cells,
thereby playing an important role in suppressing
invasion.
PC induces G0/G1 cell cycle arrest of MDA MB 231 breast
cancer cells
Since PC inhibited cell proliferation, we further deter-
mined to assess the role of PC in cell cycle progression
of MDA MB 231 cells by flow cytometry. Results show
that PC induced significant G0/G1 cell cycle arrest. In
comparison to untreated controls, there is an increase in
percentage of cells in G0/G1 phase (62.1 ± 1.1 % Vs 73.2 ±
0.2 %) with a concomitant decrease in the percentage of
cells in S (18.4 ± 1.1 % Vs 14.3 ± 0.04 %) and G2-M phases
(17.7 ± 3.5 % Vs 10.7 ± 0.4 %) of the cell cycle (Table 3).
With PC treatment, there is an increase of about 1.17
fold in number of cells in G0/G1 phase as compared to
untreated controls, suggesting the role of PC in inhibit-
ing entry into S-phase (Fig. 3a). Further to establish the
fact that PC inhibits S-phase entry, we tested for the
levels of cell cycle regulatory proteins involved in G1 to
S transition -Cyclin E, CDK2, and CDK inhibitor p21 by
qPCR analysis. We observed that mRNA levels of both
Cyclin E and CDK2 decreased by 1.60 and 1.64 fold
respectively and of p21 increased by 1.81 fold in com-
parison to untreated control, strongly indicating the
triggering of G1 arrest and blocking S phase entry
(Fig. 3b-d).
PC induces apoptosis of MDA MB 231 breast cancer cells
As PC is known to induce apoptosis in cancer cells
[8, 9, 13, 20], we next determined to study the extent of
apoptosis in MDA MB 231 cells by Annexin V PE and
7AAD staining. Results showed that PC treated MDA MB
231 cells demonstrated a high induction of apoptosis in
comparison to untreated controls. The percentage of
apoptotic cells increased gradually from 2.69 % in un-
treated controls to 14.99 % and 21.43 % in IC25 and IC50
treated cells with a fold increase of 5.57 and 7.96 respect-
ively (Fig. 4a and Table 4). Consistent with this, results
from western blot analysis for phospho-H2AX (γH2AX)
revealed a dose dependent increase in γH2AX levels upon
treatment with PC - an indicative of accumulating DNA
double stranded breaks (Fig. 4b). Further to gain a deeper
insight into the mechanism of apoptosis induced by PC,
Table 2 IC50 values
Cell line IC50 (μM) 24H
Breast cancer cell lines
MDA MB 231 5.98 ± 0.95
HBL 100 8.31 ± 1.59
BT-474 8.45 ± 0.94
MCF-7 15.43 ± 2.11
SKBR-3 15.73 ± 0.74
Normal cells
MCF10A >20
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we next tested the release of cytochrome C - an important
initiator step for the activation of caspases. Western blot
results for cytochrome C revealed a sustained release of
cytochrome C from 1.5 h onwards with maximal release
at 6 h, indicating initiation of apoptosis (Additional file 1:
Figure S1). Consistently, qPCR analysis for apoptotic
markers like Bax, Bcl2 and caspases 9 in PC treated cells
showed that there is a change in the Bcl-2/Bax ratio
(Increased Bax (2.38 fold higher) to Bcl-2 (1.34 fold lower)
ratio) and a 1.72-fold increase in Caspase 9 levels in com-
parison to untreated controls (Fig. 4 c-e) which was sup-
ported by Western blot analysis for cleaved caspase 9
(Additional file 2: Figure S2). Taken together these results
suggest that PC is cytotoxic and induces apoptosis in
MDA MB 231 cells in a dose and time dependent
manner.
PC targets MAPK signaling in MDA MB 231 breast cancer
cells
We next aimed to determine the specific signaling path-
way targeted by PC to induce apoptosis in MDA MB
231 breast cancer cells. We screened for several
signaling pathways that are likely to be involved in cell
growth, proliferation, and survival of TNBC’s. [21] Re-
sults show that PC treatment did not alter the phosphor-
ylation levels of both AKT and NFkB-p65, (Additional
file 3: Figure S3A and S3B) whereas a significant de-
crease in the phosphorylation of ERK1/2 was observed
in as early as 30 min following treatment with maximal
decrease at 90 min (Fig. 5a). Consistently, we also ob-
served a significant (1.14 fold) decrease in the mRNA
levels of MCL-1 - a downstream target of ERK1/2 signal-
ing and a key regulator for TNBC survival (Fig. 5b).
PC inhibits COX-2 expression in breast cancer cells
Since TNBC’s are known for high expression of COX-2
and COX-2 downregulation plays a key role in apoptosis
[22]. We next determined the levels of COX-2 protein
and mRNA by Western blot and qPCR, respectively. Re-
sults showed that PC treated cell showed a decrease in
COX-2 protein and mRNA levels (Fig. 6a). Consistently,
we also observed a decrease in PGE2 production (a
downstream product of COX-2) in arachidonic acid
stimulated MDA-MB-231 cells upon treatment with PC.
Fig. 1 Growth inhibitory effects of Phycocyanin on breast cancer cells. a The anti-proliferative effects of phycocyanin on a panel of breast cancer
cells and MCF10A cells were analyzed by neutral red staining assay. Data are expressed as mean ± SD; (n = 3). b Representative micrographs from
random fields of view (magnification 20X) of indicated cells treated with and without phycocyanin. c Phycocyanin at different concentrations in-
hibits clonogenecity of MDA MB 231 cells as determined by clonogenic cell survival assay. Quantitative representation of reduction in num-
ber of colonies with representative images. ***P < 0.0001 compared with untreated controls
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The basal level of PGE2 released in MDA MB 231 cells
was 29.7 pg/ml. Upon stimulation with 10 μM arachi-
donic acid for 18 h and followed by treatment to PC for
24 h, there was a decrease in the level of PGE2 from
114.6 pg/ml to 70.7 pg/ml (Fig. 6b).
PC inhibits channel formation of breast cancer cells
It is known that high COX-2 expression in TNBCs pro-
motes increased angiogenesis which is in turn mediated
by key regulators like VEGFR2 and MMP-9 [23]. Based
on this, we next sought to determine the kinetics of vas-
cular channel formation in MDA MB 231 cells upon
treatment with PC by vasculogenic mimicry assay. Re-
sults showed that 3 μM dose of PC significantly inhib-
ited the number of vascular channels formed as
compared with untreated control cells (Fig. 7a). Subse-
quently, qPCR analysis showed a significant decrease in
the mRNA levels of VEGFR2 and MMP-9 by 1.17 and
5.55 fold, respectively (Fig. 7b-c). Therefore failure of
cells to form patterned networks on matrigel and de-
crease in transcription of genes involved in regulating
angiogenesis endorses the antiangiogenic potential of
PC.
PC is non-toxic to blood cells
We next determined the PC’s compatibility to RBC’s and
platelet aggregation inhibitory effect by in vitro
hemolytic assay and aggregation assay. Results showed
no aberrant morphological changes to RBC’s and
showed inability to cause platelet aggregation upon
treatment with PC- indicating that PC is safe to use for
therapy (Additional file 4: Figure S4A and S4B).
Discussion
It is well known that breast cancer is not the one form
of cancer. Gene expression profiling has revealed five
Fig. 2 Phycocyanin inhibits cell migration in MDA MB 231 cells. a Percentage of cell migration into the wound scratch with and without treatment
with PC was quantified and compared against that of controls. Representative images of wound healing at 0 and 24 h following scratch induction and
PC treatment. b Assessment of cellular aggregation by hanging drop aggregation assay showed increased cell-cell adhesion (>20 aggregates) in PC
treated MDA MB 231 cells (arrows indicate >20 aggregates). (***P < 0.0001 compared with untreated controls) (c) Confocal scanning microscopy
analysis for phalloidin in MDA MB 231 cells showed microfilament network collapse after PC treatment
Table 3 DNA content analysis
CELL LINE SUBG0/G1 (%) G0/G1 (%) S (%) G2-M (%)
MDA MB 231 CONTROL 2.4 ± 1.6 62.1 ± 1.1 18.4 ± 1.1 17.7 ± 3.5
PC-IC50 1.7 ± 0.3 73.2 ± 0.2 14.3 ± 0.04 10.7 ± 0.4
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molecular subtypes and diagnosis is based upon the
presence or absence of hormone receptor-related genes
ER, PR and HER2 [24]. Triple-negative breast cancer is
one such subtype that is clinically negative for these
three receptors and accounts for 10–17 % of all breast
carcinomas [25]. It is characterized by its highly aggres-
sive behavior, increased metastasis, poor prognosis and
lack of targeted therapies - thus intensifying the need for
identifying novel therapeutic strategies for this subset of
patients.
Over the last few decades application of natural prod-
ucts for chemoprevention/therapy has gained import-
ance [26]. More recently, pharmacologically active
marine derived compounds have been shown to have
potent anti-cancer activity with little or no toxic side ef-
fects [7, 27]. Induction of apoptosis is the key mechan-
ism by which cytotoxicity is achieved with these
compounds [28]. One such compound is the biliprotein
PC from the edible Arthrospira platensis which in the
recent past has been investigated for its anticancer ef-
fects on solid malignancies [29]. To the best of our
knowledge, this is the first study to demonstrate the
anti-cancer effect of PC on breast cancer cell - in par-
ticular TNBC cell line. The study also highlights the
mechanism underlying PCs cytotoxic, anti-metastatic
and anti-angiogenic effects. Our study clearly demon-
strated that PC selectively targets MAPK signaling path-
way and it also altered the expression of proteins
involved in cell cycle and cell survival by which it medi-
ates its growth inhibitory and apoptosis.
Since tissue invasion and metastasis are the main
causes for mortality in triple negative breast cancer [30],
we investigated the effects of PC on cellular migration
and aggregation behavior of MDA MB 231. Our results
demonstrated that PC treatment has a direct effect on
the aggressive behavior of cells and is evident by de-
creased migration potential associated with disruption of
actin microfilaments and increased aggregative property.
It is well known that cyclin dependent kinases play
crucial role in regulation of cell cycle progression.
Deregulated activity of these kinases contributes to in-
creased cellular proliferation which has been reported in
a wide variety of human cancers [31]. Our initial screen-
ing results indicated that PC inhibits proliferation of
MDA MB 231 cells and its inhibition correlated well
with a decrease in the expression levels of Cyclin E and
CDK-2, which are required to mediate the G1-S transi-
tion. We also observed an increase in the levels of tumor
suppressor p21 that disables the cells to start DNA syn-
thesis, thus confirming arrest at G1/S boundary.
Decrease in CDK-2 levels induces sustained DNA
damage and G1 arrest thereby pushing cells to enter
apoptosis [31]. It is accepted that transformed cells ac-
quire the ability to breach this dogma and fail to enter
the apoptotic pathway resulting in uncontrolled prolifer-
ation. In our study, we observed significant induction of
apoptosis in PC treated breast cancer cells indicative of
PC‘s ability to activate the apoptotic pathway.
Arrest of cell cycle and activation of apoptosis are cel-
lular responses to DNA damage [32]. Since TNBCs are
characterized by genomic instability as a consequence of
double-stranded DNA repair deficiency, DNA alkylating
agents are currently used as conventional therapeutic
agents [33–35]. Moreover, DNA damaging agents are
more effective against rapidly proliferating cells thus
making cancer cells more susceptible than their normal
Fig. 3 Phycocyanin induces G1 phase arrest in MDA MB 231 cells. a CeIl cycle analysis showing increased accumulation of cells in G0/G1 phase
when treated to phycocyanin with representative histograms. qPCR analysis for genes involved in G1 phase arrest (b) Cyclin E (c) Cdk2 and (d)
p-21. GAPDH was used as internal control for normalization. (***P < 0.0001, ** P < 0.002 compared with untreated controls)
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counterparts [36]. Therefore, the focus is on dietary phy-
tochemicals which could trigger damage to cellular
DNA, thereby accelerating cell death. We observed a
pronounced increase in γ-H2AX in a time-dependent
manner following PC treatment which clearly correlated
with cell cycle arrest and increased apoptosis.
It is widely accepted that apoptosis is controlled by the
Bcl-2 family members. Altered expression of the Bcl-2
family of proteins: Bax and Bcl-2 resulting in changing
the Bcl-2/Bax ratio is frequently implicated in breast
cancers and is often associated with poor survival
[37–41]. As reported previously in other cancers types
[12, 42], we also observed a change in the Bcl-2/Bax
ratio with increase in cytochrome C and caspase 9
levels with PC treatment.
Most tumor cells show increased MAPK signaling by
which they survive and avoid undergoing apoptosis [43].
In our study we observed PC downregulated ERK1/2
signaling, which could be one of the reason for pushing
cells from survival to apoptosis. This decreased phos-
phorylation of ERK1/2 correlated with decreased expres-
sion of Mcl-1, an emerging target for treatment of
chemoresistant TNBC. Taken together these results sug-
gest that PC induced apoptosis in MDA MB 231 cells
through inactivation of ERK pathway, and inhibition of
MCL-1.
The biological function of COX-2 is to convert arachi-
donic acid into prostaglandins. This inducible enzyme is
deregulated in many human tumors including tumors of
Fig. 4 Phycocyanin induces apoptosis in MDA MB 231 cells. a Quantitative representation of early apoptotic cells at IC25 &50 doses at the end of
6 h treatment with PC as analyzed by PE annexin V and 7 AAD staining with representative scatter plots showing shift of cells from live to early
apoptosis. b Western blot analysis for phospho-H2AX (C) qPCR analysis of apoptotic markers in MDA MB 231 cells. qPCR analysis for (c) BAX,
(d) Bcl-2 and (e) caspase 9. GAPDH was used as internal control for normalization (***P < 0.0001, ** P = 0.001, *P = 0.01 compared with
untreated controls)
Table 4 Percentage of cells undergoing apoptosis
MDA MB 231 Live Early apoptotic Late apoptotic Dead
CONTROL 96.39 ± 0.72 2.69 ± 0.26 0.91 ± 0.43 0.01 ± 0.02
PC - IC25 83.65 ± 1.47 14.99 ± 1.49 1.34 ± 0.25 0.01 ± 0.02
PC - IC50 59.18 ± 1.89 21.42 ± 2.30 12.24 ± 0.77 7.15 ± 0.85
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the breast and plays a key role in tumor progression and
chemoresistance [44, 45]. Several pre-clinical studies
using celecoxib have shown anti-tumour capacities
linked with induction of apoptosis and activation of cas-
pases following COX-2 inhibition [46, 47]. Reduction in
COX-2 expression and PGE-2 production levels con-
firmed apoptosis induction in PC treated cells.
Highly invasive and metastatic breast cancer cells
with high COX-2 levels form patterned vascular chan-
nels on matrigel. PGE-2 a tightly regulated product of
COX, behaves as a mitogen facilitating angiogenisis
[48]. Our study also showed that PC via inhibiting
COX-2 levels decreased anti-angiogenic effects in
TNBCs. Another important highlight of this study is
that PC did not cause significant toxicity to normal
cells and blood cells, suggesting that PC possess se-
lectivity between cancerous and noncancerous cells.
Conclusion
In conclusion, this study demonstrated that PC in TNBC
cells (i) inhibits the proliferation (ii) promotes change in
the Bcl-2/Bax ratio (iii) inhibits metastasis via actin cyto-
skeleton disruption (iv) suppresses angiogenesis and (v)
down-regulates MAPK signaling pathways to elicit cell
death (Fig. 8). This study proposes that PC could be
used as a promising anti-cancer therapeutic agent in
TNBCs without toxicity to normal cells.
Fig. 5 Phycocyanin targets MAPK signaling pathway. a MDA MB 231 cells were treated with 3 μM concentration of PC at the indicated time
points and phospho ERK (P42/44 MAPK) and total ERK levels were analysed by Western blotting. b qPCR analysis for MCL-1 gene expression in
MDA MB 231 cells treated with or without PC. (** P = 0.009 compared with untreated controls)
Fig. 6 Phycocyanin suppressed COX-2 expression and PGE2 production. MDA-MB-231 cells were treated with phycocyanin at indicated
concentrations for 24 h and (a) COX-2 protein and mRNA levels were analyzed by Western blotting and qPCR respectively. b PGE2 levels
in arachidonic acid stimulated and phycocyanin treated MDA-MB-231 cells as analyzed by ELISA. (** P = 0.004 compared with
untreated controls)
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Fig. 7 Phycocyanin inhibits vascular channel formation in MDA MB 231 cells (a) Representative phase contrast images of vascular channels
monitored through 0–10 h following treatment with 3 μm PC. Inhibition of vascular channel formation was evident in as early as 6 h indicating
potent anti-angiogenic effects (b) qPCR analysis for VEGFR2 and MMP-9 genes in MDA MB 231 cells treated with 3 μM or without PC for 24 h.
(# P = 0.064, ***P < 0.0001 compared with untreated controls)
Fig. 8 Schematic representation of PC action in MDA MB 231 cells. PC in MDA MB 231 cells (i) inhibits the proliferation (ii) inhibits metastasis via
actin cytoskeleton disruption (iii) promotes change in the Bcl-2/Bax ratio (iv) suppresses angiogenesis and (v) down-regulates MAPK signaling
pathways to elicit cell death
Ravi et al. BMC Cancer  (2015) 15:768 Page 11 of 13
Additional files
Additional file 1: Figure S1. Phycocyanin induces apoptosis in MDA
MB 231 cells. Increased cytochrome C expression after 6 h of PC
treatment as analyzed by western blot. (PNG 83 kb)
Additional file 2: Figure S2. Phycocyanin induces apoptosis in MDA
MB 231 cells. Phycocyanin (5 μM) treatment at mentioned time points
showed cleaved caspase levels. (PNG 60 kb)
Additional file 3: Figure S3. Phcocyanin targets MAPK signaling
pathway. Phycocyanin (3 μM) treatment at mentioned time points did
not alter the phosphorylation levels of both (A) AKT and (B) NFkB-p65.
(PNG 212 kb)
Additional file 4: Figure S4. Phycocyanin is non-toxic to blood cells.
Phycocyanin (20 μM) treated (A) RBC’s did not show aberrant
morphological changes and (B) Platelet failed to aggregate after 2 h.
(PNG 513 kb)
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